RESUMO
BACKGROUND: Human immunodeficiency virus 1 (HIV-1) tissue reservoirs remain the main obstacle against an HIV cure. Limited information exists regarding cannabis's effects on HIV-1 infections in vivo, and the impact of cannabis use on HIV-1 parenchymal tissue reservoirs is unexplored. METHODS: To investigate whether cannabis use alters HIV-1 tissue reservoirs, we systematically collected 21 postmortem brain and peripheral tissues from 20 men with subtype C HIV-1 and with suppressed viral load enrolled in Zambia, 10 of whom tested positive for cannabis use. The tissue distribution and copies of subtype C HIV-1 LTR, gag, env DNA and RNA, and the relative mRNA levels of cytokines IL-1ß, IL-6, IL-10, and TGF-ß1 were quantified using PCR-based approaches. Utilizing generalized linear mixed models we compared persons with HIV-1 and suppressed viral load, with and without cannabis use. RESULTS: The odds of tissues harboring HIV-1 DNA and the viral DNA copies in those tissues were significantly lower in persons using cannabis. Moreover, the transcription levels of proinflammatory cytokines IL-1ß and IL-6 in lymphoid tissues of persons using cannabis were also significantly lower. CONCLUSIONS: Our findings suggested that cannabis use is associated with reduced sizes and inflammatory cytokine expression of subtype C HIV-1 reservoirs in men with suppressed viral load.
Assuntos
Citocinas , Infecções por HIV , HIV-1 , Carga Viral , Humanos , Masculino , HIV-1/genética , HIV-1/efeitos dos fármacos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , Adulto , Citocinas/metabolismo , Citocinas/genética , Provírus/genética , Pessoa de Meia-Idade , Zâmbia , DNA Viral , Antirretrovirais/uso terapêutico , Encéfalo/virologia , Encéfalo/metabolismo , Adulto Jovem , Uso da Maconha/metabolismoRESUMO
BACKGROUND: Genotypic resistance test (GRT) performed in peripheral blood mononuclear cells (PBMC) represents a chance to evaluate resistance in virologically suppressed HIV infected patients. OBJECTIVES: To evaluate the impact of baseline resistance detected through PBMC GRT on virological rebound after switching treatment. STUDY DESIGN: Baseline genotypic susceptibility scores (GSS) from PBMC GRT (DNA-GSS) and from previous cumulative plasma GRTs (when available, pRNA-GSS) were evaluated. Survival analysis was used to assess the probability and predictors of virological rebound (VR). RESULTS: 227 virologically suppressed patients were analysed. Twenty-four months after switching therapy, the probability of VR was 15.3%. Patients showing an intermediate or full resistant DNA-GSS had a higher probability of experiencing VR compared to those carrying a fully susceptible DNA-GSS (27.2% vs. 13.7%, pâ¯=â¯0.001). By multivariable Cox regression, patients with an intermediate/full resistant DNA-GSS, with a nadir CD4 count <100â¯cell/mm3 and with a shorter time of previous virological suppression showed a higher adjusted hazard of experiencing VR. In a sub-group of 114 patients with previous plasma GRTs available, patients with an intermediate or fully resistance showed by both GSSs (from plasma and PBMCs) had the highest probability of experiencing VR. CONCLUSIONS: Resistance detected in proviral DNA, together with a low nadir CD4 count and a short previous virological control, predicts VR after therapy switching in virologically suppressed patients. PBMC GRT can be a useful tool for tailoring treatment switch, especially if paired with information about previous cumulative resistance and previous viro-immunological history.
Assuntos
Antirretrovirais/uso terapêutico , Farmacorresistência Viral , Substituição de Medicamentos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , HIV-1/efeitos dos fármacos , Leucócitos Mononucleares/virologia , Adulto , Contagem de Linfócito CD4 , DNA Viral/genética , Feminino , Genótipo , Técnicas de Genotipagem , Infecções por HIV/diagnóstico , HIV-1/genética , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Prognóstico , Provírus/genética , Análise de Sobrevida , Falha de TratamentoRESUMO
Moloney Murine Leukemia Virus (M-MLV) proviral DNA is transcriptionally silenced in embryonic cells by a large repressor complex tethered to the provirus by two sequence-specific DNA binding proteins, ZFP809 and YY1. A central component of the complex is Trim28, a scaffold protein that regulates many target genes involved in cell cycle progression, DNA damage responses, and viral gene expression. The silencing activity of Trim28, and its interactions with corepressors are often regulated by post-translational modifications such as sumoylation and phosphorylation. We defined the interaction domains of Trim28 and YY1, and investigated the role of sumoylation and phosphorylation of Trim28 in mediating M-MLV silencing. The RBCC domain of Trim28 was sufficient for interaction with YY1, and acidic region 1 and zinc fingers of YY1 were necessary and sufficient for its interaction with Trim28. Additionally, we found that residue K779 was critical for Trim28-mediated silencing of M-MLV in embryonic cells.
Assuntos
Vírus da Leucemia Murina de Moloney/fisiologia , Provírus/genética , Infecções por Retroviridae/veterinária , Doenças dos Roedores/metabolismo , Proteína 28 com Motivo Tripartido/metabolismo , Fator de Transcrição YY1/metabolismo , Motivos de Aminoácidos , Animais , Inativação Gênica , Camundongos , Vírus da Leucemia Murina de Moloney/genética , Ligação Proteica , Domínios Proteicos , Provírus/metabolismo , Infecções por Retroviridae/genética , Infecções por Retroviridae/metabolismo , Infecções por Retroviridae/virologia , Doenças dos Roedores/genética , Doenças dos Roedores/virologia , Proteína 28 com Motivo Tripartido/química , Proteína 28 com Motivo Tripartido/genética , Fator de Transcrição YY1/química , Fator de Transcrição YY1/genéticaRESUMO
Switch of antiretroviral therapy in virologically suppressed HIV-infected patients is frequent, to prevent toxicities, for simplification or convenience reasons. Pretherapeutic genotypic resistance testing on RNA can be lacking in some patients, which could enhance the risk of virologic failure, if resistance-associated mutations of the new regimen are not taken into account. Proviral DNA resistance testing in 69 virologically suppressed patients on antiretroviral treatment with no history of virological failure were pair-wised compared with pre-ART plasma RNA resistance testing. The median time between plasma (RNA testing) and whole blood (proviral DNA testing) was 47 months (IQR 29-63). A stop codon was evidenced in 23% (16/69) of proviral DNA sequences; these strains were considered as defective, non-replicative, and not taken into consideration. Within the non defective strains, concordance rate between plasma RNA and non-defective proviral DNA was high both on protease (194/220 concordant resistance-associated mutations=88%) and reverse transcriptase (28/37 concordant resistance-associated mutations=76%) genes. This study supports that proviral DNA testing might be an informative tool before switching antiretrovirals in virologically suppressed patients with no history of virological failure, but the interpretation should be restricted to non-defective viruses.
Assuntos
DNA Viral/genética , Técnicas de Genotipagem/métodos , Infecções por HIV/virologia , HIV-1/genética , Testes de Sensibilidade Microbiana/métodos , Provírus/genética , Humanos , RNA Viral/genéticaRESUMO
OBJECTIVES: In the context of a rilpivirine/emtricitabine/tenofovir disoproxil fumarate switch in HIV-1-infected patients with at least 1 year of virological success, we determined whether proviral DNA is an alternative to plasma HIV RNA for resistance genotyping. METHODS: Resistance-associated mutations (RAMs) in DNA after at least 1 year of virological success [viral load (VL) <50 copies/mL] were compared with those identified in the last plasma RNA genotype available. Rilpivirine/emtricitabine/tenofovir disoproxil fumarate RAMs studied were K65R, L100I, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C and M230I/L in the RT. We studied patients without virological failure (VF) and with at least 1 VF (two consecutive VLs >50 copies/mL). Kappa's coefficient was used to measure agreement between the DNA and RNA genotypes. RESULTS: In patients without VF (nâ=â130) and with VF (nâ=â114), RNA and DNA showed resistance to at least one drug of the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination in 8% and 9% and in 60% and 45%, respectively. For rilpivirine RAMs, correlation between RNA and DNA was higher in patients without VF than in patients with VF (kappaâ=â0.60 versus 0.19, Pâ=â0.026). Overall, the prevalence of RAMs was lower in DNA than in RNA. CONCLUSIONS: Incomplete information provided by the DNA genotypic test is more notable in patients with VF, suggesting that all resistance mutations associated with prior VF have not been archived in the proviral DNA or decreased to a level below the threshold of detection. In the case where no historical plasma genotypic test is available, DNA testing might be useful to rule out switching to rilpivirine/emtricitabine/tenofovir disoproxil fumarate.
Assuntos
Fármacos Anti-HIV/uso terapêutico , DNA Viral/genética , Farmacorresistência Viral , Emtricitabina/uso terapêutico , Infecções por HIV/tratamento farmacológico , Rilpivirina/uso terapêutico , Tenofovir/uso terapêutico , Genótipo , Técnicas de Genotipagem/métodos , Infecções por HIV/virologia , Humanos , Testes de Sensibilidade Microbiana/métodos , Mutação , Provírus/genética , RNA Viral/genéticaRESUMO
Great Britain has been bovine leukaemia virus (BLV) disease free since 1999. We recently reported three separate incidents of BLV seropositivity on farms with home-reared cattle due to the use of colostrum replacer rather than infection with BLV (Emerg. Infect. Dis., 19, 2013, 1027). These cases were all linked via the use of the same brand of colostrum replacer. Here, we investigate further by examining multiple brands of colostrum replacer for proviral DNA and BLV antibodies. BLV antibodies were detected in 7 of the colostrum replacers tested, with PCR concurring in two cases. Thus, the use of these BLV antibody-positive colostrum replacers may also lead to false-positive serological diagnostics.
Assuntos
Colostro/virologia , Vírus da Leucemia Bovina/isolamento & purificação , Provírus/genética , Animais , Anticorpos Antivirais/análise , Bovinos , Doenças dos Bovinos/diagnóstico , Doenças dos Bovinos/imunologia , Colostro/imunologia , DNA Viral/genética , Reações Falso-Positivas , Feminino , Vírus da Leucemia Bovina/genética , Vírus da Leucemia Bovina/imunologia , Reação em Cadeia da Polimerase/veterinária , Gravidez , Reino UnidoRESUMO
Embryonic cells transcriptionally repress the expression of endogenous and exogenous retroelements. Trim28, a key player in this silencing, is known to act in a large DNA-bound complex, but the other components of the complex are not fully characterized. Here, we show that the zinc finger protein Yin Yang 1 (YY1) is one such component. YY1 binds to the long terminal repeat (LTR) region of both exogenous and endogenous retroviruses (ERVs). Deletion of the YY1-binding site from the retroviral genome leads to a major loss of silencing in embryonic cells and a coordinated loss of repressive histone marks from the proviral chromatin. Depletion of YY1 protein results in marked upregulation of expression of exogenous viruses and of selected ERVs. Finally, we report an embryonic cell-specific interaction between YY1 and Trim28. Our results suggest a major role for YY1 in the silencing of both exogenous retroviruses and ERVs in embryonic cells.
Assuntos
Células-Tronco Embrionárias/metabolismo , Inativação Gênica , Provírus/genética , Fator de Transcrição YY1/metabolismo , Animais , Sítios de Ligação , Cromatina/metabolismo , DNA Viral/genética , DNA Viral/metabolismo , Células-Tronco Embrionárias/virologia , Deleção de Genes , Células HEK293 , Histonas/metabolismo , Humanos , Camundongos , Vírus da Leucemia Murina de Moloney/genética , Vírus da Leucemia Murina de Moloney/metabolismo , Células NIH 3T3 , Proteínas Nucleares/metabolismo , Provírus/metabolismo , Proteínas Repressoras/metabolismo , Sequências Repetidas Terminais , Transcrição Gênica , Proteína 28 com Motivo Tripartido , Fator de Transcrição YY1/genéticaRESUMO
BACKGROUND: Resistance genotyping is often requested due to residual HIV viraemia or for treatment optimization, but may be unsuccessful if plasma RNA levels are too low or undetectable. Analyses of proviral HIV-DNA can provide information about the viral reservoir, because integrated DNA reflects both actively and latently infected cells. OBJECTIVES: To determine whether proviral DNA is a potential relevant alternative to HIV-RNA for resistance genotyping in this context. METHODS: The resistance mutations harboured by the proviral DNA were compared with the cumulative data for all plasma RNA genotypes previously obtained for the patient concerned. We also investigated whether various parameters, such as CD4 count, level of viraemia or drug pressure, affected the results. RESULTS: We collected 134 and 141 DNA genotypes with 443 and 462 corresponding RNA sequences for the reverse transcriptase and protease genes, respectively. The mean rates of concordance between DNA and RNA genotypes were 46.7% for nucleoside reverse transcriptase inhibitors (NRTIs), 26.3% for non-NRTIs and 43.7% for protease inhibitors (PIs). Mixtures were detected for most DNA mutations. The rate of concordant PI mutations was significantly higher for patients taking PIs at the time of DNA genotyping (48% versus 26%; P=0.004). The other factors studied had no impact. CONCLUSIONS: In the context of low or undetectable viraemia, it is difficult to reach the archived mutated DNA. Classical RNA genotyping during previous periods of virological failure remains the gold standard for documenting resistance mutations and for the monitoring of future treatments.
Assuntos
Antivirais/uso terapêutico , Farmacorresistência Viral , Infecções por HIV/virologia , HIV/genética , HIV/isolamento & purificação , Virologia/métodos , Antivirais/farmacologia , DNA Viral/genética , DNA Viral/isolamento & purificação , Genótipo , HIV/efeitos dos fármacos , Infecções por HIV/tratamento farmacológico , Humanos , Linfócitos/virologia , Testes de Sensibilidade Microbiana/métodos , Plasma/virologia , Provírus/efeitos dos fármacos , Provírus/genética , Provírus/isolamento & purificação , RNA Viral/genética , RNA Viral/isolamento & purificação , Análise de Sequência de DNA , ViremiaRESUMO
The compartmentalization of small ruminant lentivirus (SRLV) subtype A (Maedi-Visna virus) and B (caprine arthritis-encephalitis virus) variants was analyzed in colostrum and peripheral blood mononuclear cells of four naturally infected goats. Sequence analysis of DNA and RNA encompassing the V4-V5 env regions showed a differential distribution of SRLV variants between the two compartments. Tissue-specific compartmentalization was demonstrated by phylogenetic analysis in three of the four cases. In these animals colostrum proviral sequences were clustered relative to the blood viral sequences. In one goat, the blood and colostrum-derived provirus sequences were intermingled, suggesting trafficking of virus between the two tissues or mirroring a recent infection. Surprisingly, the pattern of free virus variants in the colostrum of all animals corresponded only partially to that of the proviral form, suggesting that free viruses might not derive from infected colostral cells. The compartmentalization of SRLV between peripheral blood and colostrum indicates that lactogenic transmission may involve specific viruses not present in the proviral populations circulating in the blood.
Assuntos
Vírus da Artrite-Encefalite Caprina/isolamento & purificação , Sangue/virologia , Colostro/virologia , Doenças das Cabras/virologia , Infecções por Lentivirus/veterinária , Vírus Visna-Maedi/isolamento & purificação , Animais , Vírus da Artrite-Encefalite Caprina/classificação , Vírus da Artrite-Encefalite Caprina/genética , Feminino , Cabras , Infecções por Lentivirus/virologia , Leucócitos Mononucleares/virologia , Dados de Sequência Molecular , Filogenia , Gravidez , Provírus/classificação , Provírus/genética , Análise de Sequência de DNA , Homologia de Sequência , Proteínas do Envelope Viral/genética , Vírus Visna-Maedi/classificação , Vírus Visna-Maedi/genéticaRESUMO
Seven new ovine progressive pneumonia virus (OPPV) field isolates were derived from colostrum and milk of 10 naturally OPPV-infected sheep from the US Sheep Experiment Station in Dubois, Idaho, USA. Sixteen sequences of the surface envelope glycoprotein (SU) from these seven Dubois OPPV field isolates and SU sequence from OPPV WLC1 were obtained, aligned with published SRLV SU sequences, and analyzed using phylogenetic analysis using parsimony (PAUP). Percent nucleotide identity in SU was greater than 95.8% among clones from individual Dubois OPPVs and ranged from 85.5 to 93.8% between different Dubois OPPV clones. SU sequences from Dubois OPPVs and WLC1 OPPV had significantly higher percent nucleotide identity to SU sequences from the North American OPPVs (85/34 and S93) than caprine-arthritis encephalitis virus (CAEVs) or MVVs. PAUP analysis also showed that SU sequences from the Dubois OPPVs and OPPV WLC1 grouped with other North American OPPVs (85/34 and S93) with a bootstrap value of 100 and formed one OPPV clade II group. In addition, Dubois and WLC1 SU amino acid sequences had significantly higher identity to SU sequences from North American OPPVs than CAEV or MVV. These data indicate that the seven new Dubois OPPV field isolates along with WLC1 OPPV are part of the OPPV clade II and are distinct from CAEVs and MVVs.
Assuntos
Glicoproteínas/genética , Infecções por Lentivirus/veterinária , Lentivirus Ovinos-Caprinos/classificação , Lentivirus Ovinos-Caprinos/genética , Doenças dos Ovinos/virologia , Proteínas do Envelope Viral/genética , Animais , Colostro/virologia , DNA Viral/química , DNA Viral/isolamento & purificação , Idaho , Infecções por Lentivirus/virologia , Lentivirus Ovinos-Caprinos/isolamento & purificação , Leite/virologia , Filogenia , Provírus/genética , Análise de Sequência de DNA , Homologia de Sequência de Aminoácidos , Homologia de Sequência do Ácido Nucleico , Ovinos/virologiaRESUMO
We investigated whether capsianosides, diterpene glycosides, extracted from Capsicum plants could affect human immunodeficiency virus type 1 (HIV-1) infection. Significant effect on virus infection in MAGI/CCR5 cells was neither observed for the X4 virus by capsianosides II, XI, and A, nor for an R5 virus by capsianoside G. Apparent enhancement of X4 HIV-1 infection by capsianoside G was observed and exclusively related to the usage of the CXCR4 coreceptor. The capsianoside G-treated cells had no change in the expression level of CD4, CXCR4, and CCR5, however, colocalization and capping of CD4 and CXCR4, but not of CD4 and CCR5 was observed. Our results suggested that capsianoside G enhanced X4 virus infection at the level of viral penetration through the capping and colocalization of receptors needed for infection.
Assuntos
Antígenos CD4/efeitos dos fármacos , Antígenos CD4/fisiologia , Diterpenos/farmacologia , Infecções por HIV/etiologia , Infecções por HIV/imunologia , HIV-1/patogenicidade , Oligossacarídeos/farmacologia , Receptores CXCR4/efeitos dos fármacos , Receptores CXCR4/fisiologia , Adsorção , Capsicum/química , Linhagem Celular , DNA Viral/genética , Diterpenos/química , Glicosídeos/química , Glicosídeos/farmacologia , HIV-1/efeitos dos fármacos , HIV-1/genética , Células HeLa , Humanos , Oligossacarídeos/química , Plantas Medicinais , Provírus/efeitos dos fármacos , Provírus/genética , Agregação de Receptores/efeitos dos fármacos , Transcrição Gênica/efeitos dos fármacos , TransfecçãoRESUMO
It has been reported that extracts of the spike of Prunella vulgaris (PS) exhibit anti-HIV activity at the adsorption and reverse transcription stages. In this study, the actual activity of PS in cells, kinetic analysis of the inhibitory activity of PS against HIV reverse transcriptase and the feasibility of oral administration were examined. First, to clarify whether this extract shows anti-HIV activity in cells in vitro, the number of copies of proviral DNA in HIV-exposed cells was calculated. The number of copies was significantly decreased in cells cultured in the presence of PS extract, but not in the presence of dextran sulphate. The activity of PS extract in the cells was also assessed by the drug addition test, during and after HIV adsorption. PS extract and dextran sulphate suppressed HIV production to similar levels when added after HIV adsorption. However, only PS extract suppressed HIV production at the same concentration when the drugs were added during HIV adsorption. Presumably, the penetration of the PS extract into the cells was required for this activity. Secondly, fractionated PS inhibited HIV reverse transcription in a non-competitive manner. This fractionated PS kept anti-HIV activity, but inhibited HIV replication and adsorption to a lesser extent compared to dextran sulphate. Lastly, an active component(s) was detected in plasma in vivo, after injection into the intestine, which demonstrates the feasibility of oral administration dosing.
Assuntos
Fármacos Anti-HIV/farmacologia , HIV-1/efeitos dos fármacos , Absorção Intestinal , Extratos Vegetais/farmacologia , Plantas Medicinais , Animais , Linhagem Celular/efeitos dos fármacos , Linhagem Celular/patologia , Linhagem Celular/virologia , DNA Viral/biossíntese , DNA Viral/efeitos dos fármacos , Cobaias , Transcriptase Reversa do HIV/antagonistas & inibidores , HIV-1/genética , Humanos , Provírus/efeitos dos fármacos , Provírus/genética , Transcrição Gênica , Replicação Viral/efeitos dos fármacosAssuntos
Infecções por HTLV-I/epidemiologia , Vírus Linfotrópico T Tipo 1 Humano/isolamento & purificação , Múmias/virologia , Povo Asiático , Análise por Conglomerados , Infecções por HTLV-I/transmissão , História Antiga , Vírus Linfotrópico T Tipo 1 Humano/genética , Humanos , Indígenas Sul-Americanos , Japão/epidemiologia , América Latina/epidemiologia , Prevalência , Provírus/genética , Provírus/isolamento & purificaçãoRESUMO
Umbilical cord blood cells (UCB) have become a major target population for experimental and clinical studies using transfer of genes involved in inborn enzymatic diseases. Cord blood contains hematopoietic progenitor cells at a high frequency, and expanding these cells ex vivo generates sufficient numbers of hematopoietic precursors for transplantation into adults, e.g., as supportive treatment. As clinical reports about retroviral transduction into UCB cells have not been as encouraging as the first preclinical data, we have established a retroviral transduction system that allows expansion and selection of hematopoietic progenitor cells from UCB. CD34-enriched UCB cells were transduced with a retroviral vector encoding a mutated dihydrofolate reductase cDNA that confers MTX resistance. We observed increased resistance to MTX in transduced granulocyte macrophage-colony forming units (CFU-GM) after co-culture of CD34+ UCB cells with the virus-producing cell line, or after incubation with virus-containing supernatant. The supernatant-based transduction protocol included a prestimulation with recombinant interleukin-1 (rhIL-1), rhkit-ligand, and rhIL-3 to increase the percentage of cells in S phase to greater than 50%. Using this protocol we measured a 72-fold expansion of CFU-GM and a 2.5-fold selective advantage of transduced versus nontransduced progenitor cells after exposure to low-dose methotrexate in liquid culture. Polymerase chain reaction analysis revealed integration of proviral DNA into the majority of transduced colonies before and after ex vivo expansion. The retroviral vector and transduction protocol reported here provides an experimental system for selection and expansion of retrovirally transduced progenitor/stem cells from UCB that may help improve the efficiency of current clinical gene therapy strategies.
Assuntos
Antígenos CD34/imunologia , DNA Complementar/genética , Sangue Fetal/citologia , Técnicas de Transferência de Genes , Células-Tronco Hematopoéticas/efeitos dos fármacos , Tetra-Hidrofolato Desidrogenase/genética , Resistência a Medicamentos , Antagonistas do Ácido Fólico/farmacologia , Vetores Genéticos/genética , Células-Tronco Hematopoéticas/fisiologia , Humanos , Metotrexato/farmacologia , Mutação , Provírus/genética , Retroviridae/genética , Fase S/efeitos dos fármacosRESUMO
We have previously shown that noninfected human T-cell lines express the canonical 5.7 kb mRNA coding for the type beta platelet-derived growth factor-receptor (PDGF beta-receptor), whereas HTLV-I-infected T-cell lines express a novel PDGF beta-receptor mRNA of 3.8 kb. In this report, we have extended those studies to molecularly characterize the 3.8 kb PDGF beta-receptor mRNA and show that it has resulted from integration of an apparently undeleted HTLV-I provirus into the PDGF beta-receptor gene in an orientation enabling expression of a truncated PDGF beta-receptor mRNA using the 3' HTLV-I long terminal repeat as a promoter. Further, NIH3T3 cells transfected with a plasmid containing the truncated PDGF beta-receptor ORF plasmid generate colonies in soft agar with more cells per colony than untransfected cells, or cells transfected with the Tax 1 or PDGF-B (c-sis) plasmids. These results indicate that the truncated PDGF beta-receptor protein acquires transforming capability and that HTLV-I-induced truncation of PDGF beta-receptor may correlate with HTLV-I-associated neoplasia of human T-cells.
Assuntos
Transformação Celular Neoplásica/genética , DNA Viral/metabolismo , Vírus Linfotrópico T Tipo 1 Humano/genética , Proteínas Tirosina Quinases/genética , Provírus/genética , Receptores do Fator de Crescimento Derivado de Plaquetas/genética , Linfócitos T/virologia , Integração Viral , Células 3T3 , Sequência de Aminoácidos , Animais , Sequência de Bases , Northern Blotting , Linhagem Celular Transformada , Clonagem Molecular , Sondas de DNA , DNA Complementar/genética , Humanos , Camundongos , Dados de Sequência Molecular , Plasmídeos/fisiologia , Proteínas Tirosina Quinases/fisiologia , Receptor beta de Fator de Crescimento Derivado de Plaquetas , Análise de Sequência de DNA , Linfócitos T/enzimologia , Linfócitos T/fisiologiaRESUMO
Sequential isolates from four patients under zidovudine (ZDV) therapy were obtained using PBMC coculture in the absence or in the presence of 0.25 microM ZDV. PBMC-based HIV susceptibility assay demonstrated the emergence of ZDV-resistance in the sequential isolates from the four patients. Except in one case, the isolates obtained in the presence of ZDV did not exhibit a greater resistance pattern than their counterparts obtained in the absence of the drug. In parallel, partial reverse transcriptase gene sequence was determined directly on amplified products from proviral DNA. In addition to the mutations previously described at the critical codons 41, 67, 70, 215, and 219, numerous additional mutations were found in either ZDV-sensitive or ZDV-resistant isolates. The mutation Thr215Tyr was not observed in a case of highly resistant virus (ZDV IC50 > 6.25 microM), while the mutation Lys70Arg was found in either resistant or sensitive ones. The analysis of additional mutations did not reveal any clear pattern for ZDV resistance but pointed out the existence of highly variable regions neighbouring the five critical codons. Neither nucleotide sequence nor PBMC-based susceptibility assay provided unambiguous data about pretherapy isolates or early on-therapy isolates which could predict the emergence of ZDV resistance in further samples.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/genética , HIV-1/efeitos dos fármacos , HIV-1/genética , Mutagênese/efeitos dos fármacos , Zidovudina/uso terapêutico , Fármacos Anti-HIV/farmacologia , Células Cultivadas , Técnicas de Cocultura , Códon/análise , Resistência Microbiana a Medicamentos/genética , Transcriptase Reversa do HIV/genética , HIV-1/isolamento & purificação , Humanos , Leucócitos Mononucleares/virologia , Testes de Sensibilidade Microbiana , Reação em Cadeia da Polimerase , Provírus/genética , Análise de Sequência de DNA , Zidovudina/farmacologiaRESUMO
A putative chemokine receptor that we previously cloned and termed LESTR has recently been shown to function as a co-receptor (termed fusin) for lymphocyte-tropic HIV-1 strains. Cells expressing CD4 became permissive to infection with T-cell-line-adapted HIV-1 strains of the syncytium-inducing phenotype after transfection with LESTR/fusin complementary DNA. We report here the indentification of a human chemokine of the CXC type, stromal cell-derived factor 1 (SDF-1), as the natural ligand for LESTR/fusin, and we propose the term CXCR-4 for this receptor, in keeping with the new chemokine-receptor nomenclature. SDF-1 activates Chinese hamster ovary (CHO) cells transfected with CXCR-4 cDNA as well as blood leukocytes and lymphocytes. In cell lines expressing CXCR-4 and CD4, and in blood lymphocytes, SDF-1 is a powerful inhibitor of infection by lymphocyte-tropic HIV-1 strains, whereas the CC chemokines RANTES, MIP-1 alpha and MIP-1 beta, which were shown previously to prevent infection with primary, monocyte-tropic viruses, are inactive. In combination with CC chemokines, which block the infection with monocyte/macrophage-tropic viruses, SDF-1 could help to decrease virus load and prevent the emergence of the syncytium-inducing viruses which are characteristic of the late stages of AIDS.
Assuntos
Fármacos Anti-HIV/farmacologia , Quimiocinas CXC , Quimiocinas/metabolismo , Quimiocinas/farmacologia , HIV-1/efeitos dos fármacos , Proteínas de Membrana/metabolismo , Receptores de HIV/metabolismo , Animais , Fármacos Anti-HIV/metabolismo , Ligação Competitiva , Antígenos CD4/genética , Antígenos CD4/metabolismo , Células CHO , Cálcio/metabolismo , Quimiocina CCL4 , Quimiocina CCL5/metabolismo , Quimiocina CXCL12 , Quimiocinas/genética , Cricetinae , Cricetulus , DNA Viral/metabolismo , HIV-1/metabolismo , Células HeLa , Humanos , Leucócitos Mononucleares/virologia , Ligantes , Proteínas Inflamatórias de Macrófagos/metabolismo , Macrófagos/virologia , Fusão de Membrana , Dados de Sequência Molecular , Provírus/genética , Receptores CXCR4 , TransfecçãoRESUMO
A renewed interest in the emergence and evolution of the primate T-cell lymphotropic viruses has followed the discovery of genetically distinct variants of human T-cell lymphotropic virus type I (HTLV-I) in Melanesia and Australia. Phylogenetic trees based on selected regions of the gag, pol, env and pX genes of HTLV-I from widely separated geographic regions and of simian T-cell lymphotropic virus type I (STLV-I) from African and Asian catarrhines, constructed using the neighbor-joining and maximum parsimony methods, indicated that the Australo-Melanesian and cosmopolitan strains of HTLV-I have evolved along separate geographically dependent lineages, with African STLV-I strains clustering with cosmopolitan HTLV-I strains and Asian STLV-I strains diverging from the common ancestral virus before the Australo-Melanesian HTLV-I strains. When viewed within the context of non-human primate evolution and human occupation of Australia and Melanesia, the rate of molecular change of HTLV-I and STLV-I is approximately 2.5-6.8 x 10(-7) substitutions per site per year. Overall, the sequence and phylogenetic analyses are in accord with interspecies virus transmission among non-human primates, as well as between non-human primates and humans, with independent evolution of HTLV-I in Southeast Asia and in Africa, and with dissemination of HTLV-I by forced or voluntary movements of human populations. The immunosuppressive and T-cell activation properties of HTLV-I places at added risk these Australian Aboriginal and Melanesian populations, some of which are in imminent threat of infection with human immunodeficiency virus type 1.
Assuntos
Evolução Biológica , Emigração e Imigração , Infecções por HTLV-I/virologia , Hominidae/virologia , Vírus Linfotrópico T Tipo 1 Humano/classificação , Primatas/virologia , Vírus Linfotrópico T Tipo 1 de Símios/classificação , África , América , Sequência de Aminoácidos , Animais , Sudeste Asiático , Austrália , Sequência de Bases , Linhagem Celular , DNA Viral/genética , Infecções por Deltaretrovirus/história , Infecções por Deltaretrovirus/veterinária , Infecções por Deltaretrovirus/virologia , Epitopos/genética , Feminino , Genes Virais , Infecções por HTLV-I/epidemiologia , Infecções por HTLV-I/história , História do Século XVI , História do Século XIX , História do Século XX , História Antiga , História Medieval , Vírus Linfotrópico T Tipo 1 Humano/isolamento & purificação , Humanos , Masculino , Melanesia , Dados de Sequência Molecular , Doenças dos Macacos/história , Doenças dos Macacos/virologia , Mutação , Filogenia , Primatas/classificação , Provírus/genética , Grupos Raciais/história , Alinhamento de Sequência , Homologia de Sequência de Aminoácidos , Vírus Linfotrópico T Tipo 1 de Símios/isolamento & purificação , Especificidade da Espécie , Proteínas Estruturais Virais/genéticaRESUMO
One of the salient pathological features of rheumatoid arthritis is synovial cell proliferation with bone erosion. Despite extensive investigation, the factors essential for synovial cell proliferation remain to be identified. Recent studies suggest that human T cell leukemia virus type I (HTLV-I) may play an important role in synovial overgrowth observed in patients with one type of chronic inflammatory synovitis. In order to confirm and extend these observations, we have established synovial cell clones (SCCs) from three HTLV-I carriers who demonstrated synovial overgrowth but were otherwise asymptomatic. HTLV-I proviral DNA randomly integrated into the cellular genome was present in 20-30% of SCCs. The SCCs carrying HTLV-I proviral DNA and expressing the tax gene exhibited high levels of proliferative potential. HTLV-I was found to function as a transcriptional trans-activator in these SCCs. Moreover, transfection of the tax expression plasmid into SCCs resulted in the same phenotype of increased proliferation and cytokine expression as exhibited by HTLV-I provirus-carrying and tax-expressing SCCs. These data suggest that tax plays a critical role not only in leukemogenesis but also in synovial overgrowth in humans.
Assuntos
Artrite/patologia , Vírus Linfotrópico T Tipo 1 Humano/genética , Membrana Sinovial/citologia , Artrite/genética , Artrite/microbiologia , Sequência de Bases , Divisão Celular , Células Clonais , DNA Viral/genética , Expressão Gênica , Genes pX , Substâncias de Crescimento/genética , Humanos , Técnicas In Vitro , Interleucina-1/genética , Interleucina-6/genética , Dados de Sequência Molecular , Oligodesoxirribonucleotídeos/química , Provírus/genética , RNA Mensageiro/genética , Ativação TranscricionalRESUMO
Zidovudine treatment of individuals infected with human immunodeficiency virus type 1 (HIV-1) results in HIV-1 isolates with a reduced zidovudine sensitivity in vitro. This reduction is due to mutations causing amino acid substitutions at five codons (41, 67, 70, 215, and 219) on the reverse transcriptase enzyme of HIV. HIV-1 isolates were obtained 8 to 69 weeks after therapy discontinuation from 10 patients at different stages of disease. Zidovudine sensitivity was determined by the HeLa CD4+ plaque assay. The presence of the resistance-conferring mutations was determined by using a selective polymerase chain reaction. Sensitivity could be determined for six isolate pairs: one showed a decline in the 50% inhibitory zidovudine concentration after therapy discontinuation; four pairs did not show a change. The majority of changes in the five codons in isolates from all 10 patients were the result of a relative increase in the wild-type sequence. Complete changes from mutant to the wild type were seen for only two codons in isolates from two patients. This study of isolates from a small group of individuals at different stages of disease, who had been taking zidovudine for 1 to 2 years, shows that a period of 1 year without zidovudine may be required to achieve a change from a mutant or mixed virus population to a wild-type virus population.